Frequently Asked Questions

If the answer to your question is not listed here, please contact us at viralvector(at)

You can submit your query via the IHfGT “Contact Us” page, via email at viralvector(at), or speak with Hub members you meet at events / visiting an institution. Check our list of upcoming events to see where we will next be attending or exhibiting.

The Hubs manufacture AAV and LV vectors at GMP grade.

The Sheffield and Bristol Hubs utilise highly efficient processes to manufacture AAV up to 50L and provide all the necessary quality assurance, regulatory certification and governance. The London Hub currently makes use of a transient production/transfection system, using adherent cells with multi-layer cell factories to produce LV and will begin manufacturing AAV vector in early 2024 using an adherent cell line system.

To find out which Hub would be recommended for your project, please email viralvector(at) or submit your query via the IHfGT “Contact Us” page.

The Innovation Hubs have highly experienced staff in the clinical development and manufacture of gene therapies and can offer a wide range of support to academics wishing to take their therapy further along the development pathway. This includes (but is not limited to): plasmid sourcing (as needed), assay development, pilot studies, small-scale pre-run testing, engineering test-runs, QC testing and batch release, regulatory support, clinical trial support. To find out how else the Hubs may be able to help you, please contact us at viralvector(at)